Skip to main content
. 2018 Jan 17;8:879. doi: 10.1038/s41598-018-19197-1

Figure 3.

Figure 3

Barrier enhancing effects of ILO and ILO-PC on human lung macrovascular and microvascular EC and the role of prostacyclin receptor. TER measurements of: (A) Human pulmonary artery EC (HPAEC) and (B) human lung microvascular EC (HLMVEC) stimulated with ILO (0.5 µM) or ILO-PC (0.5 µM). Bar graph depicts quantitative analysis of ILO- and ILO-PC-induced TER changes at the time points after agonist indicated in panels A and B by vertical lines; n = 5; **p < 0.05. (C) HPAEC were pretreated with vehicle or prostacyclin receptor small molecule inhibitor (IPi) followed by stimulation with ILO. (D) HPAEC were pretreated with vehicle or prostacyclin receptor small molecule inhibitor CAY10441 (IPi, 0.2 µM) followed by stimulation with ILO-PC. Bar graph depicts quantitative analysis of IPi inhibitory effects on ILO- and ILO-PC-induced TER elevation at maximal point. Data are expressed as mean ± SD; n = 5; **p < 0.05. Statistical significance by two-way analysis of variance (ANOVA) and Tukey’s post hoc multiple-comparison test.